Aarti Drugs Ltd
Aarti Drugs Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY '26 growth was below expectations; volume growth of 15% in H2 is pushed into FY '27. Aarti Drugs anticipates a new growth phase as strategic investments begin aligning, with more significant financial impact expected in upcoming quarters due to increased capacity utilization and improved product mix.
From Aarti Drugs Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY '26 growth was below expectations; volume growth of 15% in H2 is pushed into FY '27.
- Expected volume growth of 12% to 15% in FY '27 driven mainly by new projects (salicylic acid and Sayakha amines).
- Existing product basket projected to deliver single-digit volume growth.
- Formulations, especially oncology and exports, expected to grow, with formulations playing a larger role in future revenue.
- Ramp-up of Sayakha plant utilization expected from 30% to 50% by March/April 2026, reaching 75% thereafter, supporting volume growth.
- Stabilizing realizations and improving demand trend from January 2026 indicate a positive sales momentum going forward.
- Expanding regulated market sales (Europe, U.S.) with approvals expected to enhance revenue and improve gross margins.
Profitability & Margins
See what Aarti Drugs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- INR 150-200 crores annual capex expected for next 2 years, covering new projects and maintenance.
- Investments include oncology dossier development, formulation expansion, and brownfield expansions.
- Greenfield projects nearing completion; ramp-up expected within 6-24 months for Sayakha and salicylic acid plants.
- Plans to expand metformin facility to 2,500-3,000 tons/month (currently 1,450-1,500 tons), including US FDA approvals and potential ANDA launch via Pinnacle.
- Capacity expansion for cardiovascular and antifungal products.
- Exploring CDMO opportunities in chlorosulfonation chemistry and methylamine derivatives.
- Strategic focus on backward integration, increasing operational efficiency, and entry into regulated and semi-regulated markets.
- Capex also includes energy improvements like large cogen boiler at Baddi.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Aarti Drugs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹720 Cr, net profit ₹55 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Drugs Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Aarti Drugs Ltd Q3 FY26 results?
FY '26 growth was below expectations; volume growth of 15% in H2 is pushed into FY '27. Aarti Drugs anticipates a new growth phase as strategic investments begin aligning, with more significant financial impact expected in upcoming quarters due to increased capacity utilization and improved product mix.
What is Aarti Drugs Ltd share price analysis?
Aarti Drugs Ltd currently shows a neutral. The stock trades at a P/E of 19.7 with a market cap of ₹3,800 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Drugs Ltd planning capital expenditure?
INR 150-200 crores annual capex expected for next 2 years, covering new projects and maintenance.
Keep Aarti Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.